Artiva Biotherapeutics Halts Autoimmune Cell Therapy Trial After Two Patient Deaths

Artiva Biotherapeutics is shutting down its clinical trial of an experimental cell therapy for autoimmune diseases following the deaths of two participants. The San Diego-based company had been testing AlloNK, an off-the-shelf natural killer cell therapy, in patients with lupus nephritis. The trial's stoppage marks a significant setback for the emerging field of applying cancer cell therapy strategies to autoimmune conditions, which has attracted major investment from pharmaceutical companies. While the specific causes of death were not disclosed, the fatalities raise safety concerns about using potent immune-modulating therapies in patients whose conditions are not immediately life-threatening. The news sent ripples through the biotech sector, as several other companies are pursuing similar approaches for diseases like lupus, rheumatoid arthritis, and multiple sclerosis. Analysts note that the autoimmune cell therapy space may face increased regulatory scrutiny following this incident. Artiva, which went public in 2021, had positioned AlloNK as a potentially safer alternative to autologous CAR-T therapies due to its off-the-shelf nature. The company's stock plummeted on the announcement. Moving forward, the field will need to carefully balance efficacy with safety, especially in patient populations that have other treatment options available.